| Price | $3.72 |
| Year Range | $2.08 – $5.34 |
| Market Cap | $365M |
| Industry | Biotechnology |
What Is Galectin Therapeutics’s AI Stock Analysis?
Galectin Therapeutics’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Galectin Therapeutics’s momentum in near-real time.
Galectin Therapeutics (GALT) has an AltIndex AI Score of 47/100, currently a Hold signal. The AI Score distills Galectin Therapeutics's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Galectin Therapeutics’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Galectin Therapeutics — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving GALT’s AI Score?
Fundamentals
Net income for the last quarter was $-9.1M. This represents a decrease of 80.60% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 21.17%, which may be a cause for concern. Ebitda for the last quarter was $-830,000. This is an increase of -72.85% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -85.47%, suggesting positive year-over-year growth.
See Galectin Therapeutics’s earnings and insider transactions.
Technicals
Today's stock price is $3.64. This represents a decrease of 10.12% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 22.88%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $3.77, which is lower than the previous SMA10 of $3.80. This suggests a potential downward trend in price movement. The RSI is 62.6, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
The business outlook among employees at Galectin Therapeutics is low (an estimate of only 0% of employees have a positive outlook), a concerning sign. Galectin Therapeutics has an estimate of 9,000 visitors to their webpage. The number of visitors is down by -10% in the last couple of months, a worrisome trend as this can indicate a loss in customers.
Explore Galectin Therapeutics’s job postings, web traffic and app downloads.
Sentiment & social
Galectin Therapeutics has 730 followers on their Twitter page, with no meaningful increase or decrese in the last couple of months.
Track Galectin Therapeutics’s market sentiment.
Frequently Asked Questions: Galectin Therapeutics AI Stock Analysis
Galectin Therapeutics's AltIndex AI Score is 47/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Galectin Therapeutics a Hold (47/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Galectin Therapeutics — company overview, fundamentals, technicals and alternative data, with a recommendation. See the GALT AI Score or sign up to read the full thesis.
